Research Article Volume 21 Issue 8 - 2026

High Protein Versus High Carbohydrate Energy Restricted Diets Effects on Glycemic Status, Cardiometabolic Risk Markers, and Body Composition in Adults with Type 2 Diabetes: A Randomized Controlled Clinical Trial

Frankie B Stentz*, John V Christman, Ann Ammons and Chris Sands

Departments of Medicine/Division of Endocrinology, Diabetes and Metabolism, The University of Tennessee Health Science Center, Memphis, Tennessee, United States

*Corresponding Author: Frankie B Stentz, Departments of Medicine/Division of Endocrinology, Diabetes and Metabolism, The Univer- sity of Tennessee Health Science Center, Memphis, Tennessee, United States.
Received: August 24, 2026; Published: October 30, 2026



Objective: A high protein weight loss diet program (HP) vs a high carbohydrate weight loss diet (HC) program were used to treat obese subjects with newly diagnosed Type 2 Diabetes (T2DM) to determine the effects on remission of T2DM, cardiovascular risk factors (CVRs), incretins (GLP-1, GIP), inflammation (IC), metabolic parameters, and muscle and fat body mass.

Research Design and Methods: Twenty-four obese women and men newly diagnosed with T2DM on no medications treatments were recruited and randomized to either a high protein-low carbohydrate (HP) (12 subjects) or a high carbohydrate-low protein (HC) (12 subjects) weight loss programs for 6 months in this randomized controlled clinical trial. Subjects were provided all foods for 6 months with daily meal menus which were dispensed weekly along with weight determinations. At baseline Oral Glucose Tolerance Test (OGTT) and Meal Tolerance Test (MTT) and DXA were done with determinations of glucose, insulin, inflammatory markers (IC), CVRs, incretin (GLP-1, GIP), and repeated after 6 months on the subjects on the respective diets.

Results: After 6 months on the HP diet program100% of the subjects had remission of their T2DM to Normal Glucose Tolerance (NGT), whereas only 8% of subjects on the HC diet had remission of T2DM, although both subject groups had similar significant weight losses. Insulin sensitivity, Cardiovascular risk factors, inflammatory cytokines and incretins (GLP-1, GIP) all exhibited significant improvements along with increased per cent muscle body mass with the HP compared to the HC diet group which lost muscle mass at 6 months.

Conclusion: Subjects on the HP weight loss diet program achieved 100% remission of T2DM to NGT at 6 months along with significant improvements in cardiovascular risk factors, incretins, inflammation, metabolic parameters, and muscle retention compared to the HC weight loss diet program. These improvements with the HP weight loss diet were achieved using foods available at local grocery stores at a cost of only $15 per day.

Keywords: Insulin Sensitivity; High Protein Weight Loss Diet; Exercise; Cardiovascular Risk Markers; Incretins; Inflammatory Markers

  1. Centers for Disease Control and Prevention. “National Diabetes Statistics Report, 2020” (2020). 
  2. Centers for Disease Control and Prevention. “National Obesity Statistics Report, 2020” (2020). 
  3. Al Jarad FAS., et al. “Prevalence and Risk Factors of Obesity Among Type 2 Diabetic Participants in Abha, Saudi Arabia: A Cross-Sectional Study”. Healthcare6 (2025). 
  4. Ogden CL., et al. “Prevalence of childhood and adult obesity in the United States, 2011-2012”. JAMA8 (2014): 806-814. 
  5. Hu FB., et al. “Diet, lifestyle, and the risk of type 2 diabetes mellitus in women”. New England Journal of Medicine11 (2001): 790-797. 
  6. Manson JE., et al. “Body weight and mortality among women”. New England Journal of Medicine11 (1995): 677-685. 
  7. Diabetes Prevention Program Research Group. “Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin”. New England Journal of Medicine6 (2002): 393-403. 
  8. Diabetes Prevention Program Research Group., et al. “10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study”. The Lancet9702 (2009): 1677-1686. 
  9. DeFronzo RA., et al. “Pioglitazone for diabetes prevention in impaired glucose tolerance”. New England Journal of Medicine12 (2011): 1104-1115. 
  10. Ceriello A., et al. “Why is hyperglycaemia worsening COVID-19 and its prognosis?” Diabetes, Obesity and Metabolism10 (2020): 1951-1952. 
  11. Zhang Y., et al. “The clinical characteristics and outcomes of patients with diabetes and secondary hyperglycaemia with coronavirus disease 2019: A single-centre, retrospective, observational study in Wuhan”. Diabetes, Obesity and Metabolism8 (2020): 1443-1454. 
  12. Maddaloni E. and Buzzetti R. “Covid-19 and diabetes mellitus: Unveiling the interaction of two pandemics”. Diabetes/Metabolism Research and Reviews7 (2020): e3321. 
  13. Pan XR., et al. “Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance: The Da Qing IGT and Diabetes Study”. Diabetes Care4 (1997): 537-544. 
  14. Tuomilehto J., et al. “Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance”. New England Journal of Medicine18 (2001): 1343-1350. 
  15. Perreault L., et al. “Effect of regression from prediabetes to normal glucose regulation on long-term reduction in diabetes risk: Results from the Diabetes Prevention Program Outcomes Study”. The Lancet9833 (2012): 2243-2251. 
  16. DeFronzo RA. “Banting Lecture. From the triumvirate to the ominous octet: A new paradigm for the treatment of type 2 diabetes mellitus”. Diabetes4 (2009): 773-795. 
  17. Nyenwe EA., et al. “Management of type 2 diabetes: Evolving strategies for the treatment of patients with type 2 diabetes”. Metabolism1 (2011): 1-23. 
  18. DeFronzo RA., et al. “Determinants of glucose tolerance in impaired glucose tolerance at baseline in the Actos Now for Prevention of Diabetes (ACT NOW) study”. Diabetologia3 (2010): 435-445. 
  19. Franz MJ., et al. “The evidence for medical nutrition therapy for type 1 and type 2 diabetes in adults”. Journal of the American Dietetic Association12 (2010): 1852-1889. 
  20. Larsen RN., et al. “The effect of high-protein, low-carbohydrate diets in the treatment of type 2 diabetes: A 12 month randomised controlled trial”. Diabetologia4 (2011): 731-740. 
  21. Alford BB., et al. “The effects of variations in carbohydrate, protein, and fat content of the diet upon weight loss, blood values, and nutrient intake of adult obese women”. Journal of the American Dietetic Association4 (1990): 534-540. 
  22. McManus K., et al. “A randomized controlled trial of a moderate-fat, low-energy diet compared with a low-fat, low-energy diet for weight loss in overweight adults”. International Journal of Obesity and Related Metabolic Disorders10 (2001): 1503-1511. 
  23. Larsen TM., et al. “Diets with high or low protein content and glycemic index for weight-loss maintenance”. New England Journal of Medicine22 (2010): 2102-2113. 
  24. Nordmann AJ., et al. “Effects of low-carbohydrate vs low-fat diets on weight loss and cardiovascular risk factors: A meta-analysis of randomized controlled trials”. Archives of Internal Medicine3 (2006): 285-293. 
  25. Boden G., et al. “Effect of a low-carbohydrate diet on appetite, blood glucose levels, and insulin resistance in obese patients with type 2 diabetes”. Annals of Internal Medicine6 (2005): 403-411. 
  26. Eisenstein J., et al. “High-protein weight-loss diets: Are they safe and do they work? A review of the experimental and epidemiologic data”. Nutrition Reviews7 Pt 1 (2002): 189-200. 
  27. Bray GA., et al. “Effect of dietary protein content on weight gain, energy expenditure, and body composition during overeating: A randomized controlled trial”. JAMA1 (2012): 47-55. 
  28. Noakes M., et al. “The role of red meat in the prevention and management of chronic disease: Obesity and type 2 diabetes mellitus”. Nutrition and Dietetics 64 (2007): S156-S161.
  29. American Diabetes Association. “Standards of Medical Care in Diabetes—2020”. Diabetes Care1 (2020): S1-S7. 
  30. Stentz FB., et al. “Remission of pre-diabetes to normal glucose tolerance in obese adults with high protein versus high carbohydrate diet: Randomized control trial”. BMJ Open Diabetes Research & Care1 (2016): e000258. 
  31. Kitabchi AE., et al. “Effects of high-protein versus high-carbohydrate diets on markers of beta-cell function, oxidative stress, lipid peroxidation, proinflammatory cytokines, and adipokines in obese, premenopausal women without diabetes: A randomized controlled trial”. Diabetes Care7 (2013): 1919-1925. 
  32. Stentz FB., et al. “Effect of high protein vs high carbohydrate diets on incretins, satiety and cardiovascular factors”. Diabetes1 (2014): 1825.
  33. Jenkins DJ., et al. “Glycemic index of foods: A physiological basis for carbohydrate exchange”. The American Journal of Clinical Nutrition3 (1981): 362-366. 
  34. Ludwig DS. “The glycemic index: Physiological mechanisms relating to obesity, diabetes, and cardiovascular disease”. JAMA18 (2002): 2414-2423. 
  35. Robinson SM., et al. “Protein turnover and thermogenesis in response to high-protein and high-carbohydrate feeding in men”. The American Journal of Clinical Nutrition1 (1990): 72-80. 
  36. Samaha FF., et al. “A low-carbohydrate as compared with a low-fat diet in severe obesity”. New England Journal of Medicine21 (2003): 2074-2081. 
  37. Caminhotto RO., et al. “Atkins diet program rapidly decreases atherogenic index of plasma in trained adapted overweight men”. Archives of Endocrinology and Metabolism6 (2015): 568-571. 
  38. Jenkins DJ., et al. “High-protein diets in hyperlipidemia: Effect of wheat gluten on serum lipids, uric acid, and renal function”. The American Journal of Clinical Nutrition1 (2001): 57-63. 
  39. Larosa JC., et al. “Effects of high-protein, low-carbohydrate dieting on plasma lipoproteins and body weight”. Journal of the American Dietetic Association3 (1980): 264-270. 
  40. Nuttall FQ., et al. “Effect of protein ingestion on the glucose and insulin response to a standardized oral glucose load”. Diabetes Care5 (1984): 465-470. 
  41. Krezowski PA., et al. “The effect of protein ingestion on the metabolic response to oral glucose in normal individuals”. The American Journal of Clinical Nutrition6 (1986): 847-856. 
  42. Eng C., et al. “Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: A systematic review and meta-analysis”. The Lancet9961 (2014): 2228-2234. 
  43. Ahrén B and Schmitz O. “GLP-1 receptor agonists and DPP-4 inhibitors in the treatment of type 2 diabetes”. Hormone and Metabolic Research11-12 (2004): 867-876. 
  44. Davidson JA. “Advances in therapy for type 2 diabetes: GLP-1 receptor agonists and DPP-4 inhibitors”. Cleveland Clinic Journal of Medicine5 (2009): S28-S38. 
  45. Young LA and Buse JB. “GLP-1 receptor agonists and basal insulin in type 2 diabetes”. The Lancet9961 (2014): 2180-2181. 
  46. Kim W and Egan JM. “The role of incretins in glucose homeostasis and diabetes treatment”. Pharmacological Reviews4 (2008): 470-512. 
  47. Boyle PJ and Freeman JS. “Application of incretin mimetics and dipeptidyl peptidase IV inhibitors in managing type 2 diabetes mellitus”. The Journal of the American Osteopathic Association 107 (Suppl) (2007): S10-S16. 
  48. Nauck MA., et al. “The evolving story of incretins (GIP and GLP-1) in metabolic and cardiovascular disease: A pathophysiological update”. Diabetes, Obesity and Metabolism3 (2021): 5-29. 
  49. Lee MMY., et al. “Cardiovascular and kidney outcomes and mortality with long-acting injectable and oral glucagon-like peptide 1 receptor agonists in individuals with type 2 diabetes: a systematic review and meta-analysis of randomized trials”. Diabetes Care5 (2025): 846-859. 
  50. Stentz FB., et al. “High protein diet leads to prediabetes remission and positive changes in incretins and cardiovascular risk factors”. Nutrition, Metabolism and Cardiovascular Diseases4 (2021): 1227-1237. 
  51. Stentz FB., et al. “Incretins and cardiovascular effects of weight loss and remission of prediabetes”. Journal of Diabetes and Clinical Studies (2020).
  52. Te Morenga LM and Jim. “Nutrition: Its relevance in development and treatment of the metabolic syndrome”. In Nutrition, edited by Christopher Byrne and Steven Wild. Elsevier (2011).
  53. Stentz FB., et al. “Hyperglycemia and Hyperlipidemia Induced Inflammation and Oxidative Stress in Human T Lymphocytes and Salutary Effects of ω-3 Fatty Acid”. SunKrist Journal of Diabetes and Clinical Care 1 (2020): 1-9.
  54. Stentz FB. and Kitabchi AE. “Hyperglycemia-induced activation of human T-lymphocytes with de novo emergence of insulin receptors and generation of reactive oxygen species”. Biochemical and Biophysical Research Communications2 (2005): 491-495. 
  55. Stentz FB. and Kitabchi AE. “Palmitic acid-induced activation of human T-lymphocytes and aortic endothelial cells with production of insulin receptors, reactive oxygen species, cytokines, and lipid peroxidation”. Biochemical and Biophysical Research Communications3 (2006): 721-726. 
  56. Mohanty P., et al. “Glucose challenge stimulates reactive oxygen species (ROS) generation by leucocytes”. The Journal of Clinical Endocrinology & Metabolism8 (2000): 2970-2973. 
  57. Stentz FB., et al. “Proinflammatory cytokines, markers of cardiovascular risks, oxidative stress, and lipid peroxidation in patients with hyperglycemic crises”. Diabetes8 (2004): 2079-2086. 
  58. Dandona P., et al. “Inflammation: The link between insulin resistance, obesity and diabetes”. Trends in Immunology1 (2004): 4-7. 
  59. Meduri GU., et al. “Inflammatory cytokines in the BAL of patients with ARDS. Persistent elevation over time predicts poor outcome”. Chest5 (1995): 1303-1314. 
  60. Meduri GU., et al. “Plasma and BAL cytokine response to corticosteroid rescue treatment in late ARDS”. Chest5 (1995): 1315-1325. 
  61. Meduri GU., et al. “Prolonged methylprednisolone treatment suppresses systemic inflammation in patients with unresolving acute respiratory distress syndrome: Evidence for inadequate endogenous glucocorticoid secretion and inflammation-induced immune cell resistance to glucocorticoids”. American Journal of Respiratory and Critical Care Medicine7 (2002): 983-991. 
  62. Meduri GU., et al. “Persistent elevation of inflammatory cytokines predicts a poor outcome in ARDS. Plasma IL-1 beta and IL-6 levels are consistent and efficient predictors of outcome over time”. Chest4 (1995): 1062-1073. 
  63. Darif D., et al. “The pro-inflammatory cytokines in COVID-19 pathogenesis: What goes wrong?” Microbial Pathogenesis 153 (2021): 104799. 
  64. Piatti PM., et al. “Hypocaloric high-protein diet improves glucose oxidation and spares lean body mass: Comparison to hypocaloric high-carbohydrate diet”. Metabolism12 (1994): 1481-1487. 
  65. Layman DK., et al. “A reduced ratio of dietary carbohydrate to protein improves body composition and blood lipid profiles during weight loss in adult women”. The Journal of Nutrition2 (2003): 411-417. 
  66. Gleason JA., et al. “Cardiovascular risk reduction and dietary compliance with a home-delivered diet and lifestyle modification program”. Journal of the American Dietetic Association10 (2002): 1445-1451. 
  67. Howard BV., et al. “Low-fat dietary pattern and weight change over 7 years: The Women's Health Initiative Dietary Modification Trial”. JAMA1 (2006): 39-49. 
  68. Gardner C. D., et al. “Comparison of the Atkins, Zone, Ornish, and LEARN diets for change in weight and related risk factors among overweight premenopausal women: the A TO Z Weight Loss Study: a randomized trial”. JAMA9 (2007): 969-977. 
  69. Tripathy D., et al. “Elevation of free fatty acids induces inflammation and impairs vascular reactivity in healthy subjects”. Diabetes12 (2003): 2882-2887. 
  70. Haffner S. M. “Insulin resistance, inflammation, and the prediabetic state”. The American Journal of Cardiology4A (2003): 18J-26J. 
  71. Ferrannini E. “The theoretical bases of indirect calorimetry: a review”. Metabolism3 (1988): 287-301. 
  72. NIH Consensus Development Panel on Optimal Calcium Intake. “NIH Consensus conference. Optimal calcium intake”. JAMA24 (1994): 1942-1948. 
  73. Institute of Medicine. Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids. National Academy Press, Washington, D.C. (2005). 
  74. Stone N. J., et al. “2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines”. Circulation25 Suppl. 2 (2014): S1-S45. 
  75. Larkin F. A., et al. “Comparison of three consecutive-day and three random-day records of dietary intake”. Journal of the American Dietetic Association12 (1991): 1538-1542. 
  76. Stentz F. B. “Hyperglycemia- and Hyperlipidemia-Induced Inflammation and Oxidative Stress through Human T-Lymphocytes and Human Aortic Endothelial Cells (HAEC)”. In Sugars, edited by R. Rovan. IntechOpen, London, England (2021): 1-16.
  77. Matthews D. R., et al. “Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man”. Diabetologia7 (1985): 412-419. 
  78. Matsuda M. and DeFronzo R. A. “Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp”. Diabetes Care9 (1999): 1462-1470. 
  79. Luo L. and Liu M. “Adiponectin: friend or foe in obesity and inflammation”. Medical Review4 (2022): 349-362. 
  80. Seldin M. M., et al. “Myonectin (CTRP15), a novel myokine that links skeletal muscle to systemic lipid homeostasis”. Journal of Biological Chemistry15 (2012): 11968-11980. 
  81. Furuhashi M. “Fatty Acid-Binding Protein 4 in Cardiovascular and Metabolic Diseases”. Journal of Atherosclerosis and Thrombosis3 (2019): 216-232. 
  82. Pang M., et al. “Recent Advances in Epigenetics of Macrovascular Complications in Diabetes Mellitus”. Heart, Lung and Circulation2 (2021): 186-196. 
  83. Stentz F. B., et al. “Decreased cardiovascular risk factors and inflammation with remission of type 2 diabetes in adults with obesity using a high protein diet: Randomized control trial”. Obesity Pillars 4 (2022): 100047. 
  84. Gleason C. E., et al. “Determinants of glucose toxicity and its reversibility in the pancreatic islet beta-cell line, HIT-T15”. American Journal of Physiology-Endocrinology and Metabolism5 (2000): E997-E1002.
  85. Unger R. H. “Lipotoxicity in the pathogenesis of obesity-dependent NIDDM. Genetic and clinical implications”. Diabetes8 (1995): 863-870. 
  86. Gautier J. F., et al. “Biological actions of the incretins GIP and GLP-1 and therapeutic perspectives in patients with type 2 diabetes”. Diabetes and Metabolism3 Pt. 1 (2005): 233-242. 
  87. Devin J. K., et al. “Sitagliptin Decreases Visceral Fat and Blood Glucose in Women With Polycystic Ovarian Syndrome”. The Journal of Clinical Endocrinology and Metabolism1 (2020): 136-151. 
  88. Deacon C. F. “Metabolism of GIP and the contribution of GIP to the glucose-lowering properties of DPP-4 inhibitors”. Peptides 125 (2020): 170196. 
  89. Ferrannini E., et al. “Beta-cell function in obesity: effects of weight loss”. Diabetes3 (2004): S26-S33.
  90. Rothberg A. E., et al. “Weight Loss Improves beta-Cell Function in People with Severe Obesity and Impaired Fasting Glucose: A Window of Opportunity”. The Journal of Clinical Endocrinology and Metabolism4 (2020). 
  91. Lim S., et al. “Antioxidant enzymes induced by repeated intake of excess energy in the form of high-fat, high-carbohydrate meals are not sufficient to block oxidative stress in healthy lean individuals”. British Journal of Nutrition10 (2011): 1544-1551.
  92. Azadi S. M., et al. “Increased circulating level of CTRP15 in patients with type 2 diabetes mellitus and its relation with inflammation and insulin resistance”. Journal of Diabetes and Metabolic Disorders2 (2021): 1499-1504. 
  93. Hadley JT. “Adiponectin and Adiponectin Signaling”. In Cellular Endocrinology in Health and Disease. Academic Press, New York (2021): 261-287.
  94. Pisprasert V., et al. “Limitations in the use of indices using glucose and insulin levels to predict insulin sensitivity: impact of race and gender and superiority of the indices derived from oral glucose tolerance test in African Americans”. Diabetes Care4 (2013): 845-853. 
  95. Gregg E. W., et al. “Association of an intensive lifestyle intervention with remission of type 2 diabetes”. JAMA23 (2012): 2489-2496. 
  96. Lean M. E., et al. “Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial”. The Lancet10120 (2018): 541-551. 
  97. Donath M. Y. and Shoelson S. E. “Type 2 diabetes as an inflammatory disease”. Nature Reviews Immunology2 (2011): 98-107. 
  98. Wilson J. G., et al. “Cytokine profile in plasma of severe COVID-19 does not differ from ARDS and sepsis”. JCI Insight17 (2020): e140289. 
  99. Johnston C. S., et al. “Use of Novel High-Protein Functional Food Products as Part of a Calorie-Restricted Diet to Reduce Insulin Resistance and Increase Lean Body Mass in Adults: A Randomized Controlled Trial”. Nutrients11 (2017): 1182. 
  100. Ceasovschih A., et al. “Glucagon-like peptide-1 receptor agonists and muscle mass effects”. Pharmacological Research 220 (2025): 107927. 

Frankie B Stentz., et al. “High Protein Versus High Carbohydrate Energy Restricted Diets Effects on Glycemic Status, Cardiometa- bolic Risk Markers, and Body Composition in Adults with Type 2 Diabetes: A Randomized Controlled Clinical Trial”. EC Nutrition 21.8 (2026): 01-20.